But the number of researchers who draw 0.4mL when they need 0.8mL, or who cannot translate "4mg" into syringe units at their specific concentration, is staggering
Technically, when the FDA first yanked tirzepatide off its shortage list in October 2024, both 503As and 503Bs could no longer legally make copycats (with one notable exception for the smaller 503As, who could still fill individual prescriptions if there was a medical reason the patient needed a slightly different version than the brand-name drugmore on this later)
5.5 Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues Insulin and insulin secretagogues (e.g., sulfonylureas) are known to cause hypoglycemia
JMIR Formative Research , 9, e72577.
The fact that I made the 7-37 peptide at Mass General, where the clinical studies were done, turned out to be critical
Alongside glucose-dependent insulinotropic peptide (GIP), GLP-1 is an incretin